Corcept Therapeutics (NASDAQ:CORT) Files An 8-K Results of Operations and Financial Condition
Item2.02. Results of Operations and Financial Condition
Item7.01. Regulation FD Disclosure
On May1, 2017, Corcept Therapeutics Incorporated (the Company)
issued a press release announcing its financial results for the
quarter ended March31, 2017. The press release is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item2.02 and Item7.01 and the information
contained in the press release attached as Exhibit 99.1 shall not
be deemed filed for purposes of Section18 of the Exchange Act of
1934, as amended, or otherwise subject to the liabilities of that
Section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended. The information in this Item2.02 and Item7.01
and the information contained in the press release attached as
Exhibit 99.1 is not incorporated by reference into any filing
with the U.S. Securities and Exchange Commission made by the
Company, whether made before or after the date hereof, regardless
of any general incorporation language in the filing unless
specifically stated so therein.
Item9.01. Financial Statements and Exhibits
(d) Exhibits
| 99.1 |
Press Release of Corcept Therapeutics Incorporated dated May1, 2017 |
About Corcept Therapeutics (NASDAQ:CORT)
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). It has also discovered approximately three structurally distinct series of selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor, and so do not terminate pregnancy or cause other side effects associated with progesterone receptor antagonism. It has begun pre-clinical and clinical development of its lead compounds from these series. Corcept Therapeutics (NASDAQ:CORT) Recent Trading Information
Corcept Therapeutics (NASDAQ:CORT) closed its last trading session up +0.12 at 9.66 with 851,536 shares trading hands.
